James Zackheim, Head of Corporate Strategy at global biopharmaceutical company UCB, shares what he foresees as the greatest benefits through collaborations between the pharma industry with tech companies. As these new partnerships, with the help of big data and AI, could accelerate the shift towards more preventive medicine and streamline the use of readily available data, however, there is also a disruptive threat from the new tech players that pharma should prepare for.